SCHEMBL2735372

SCHEMBL2735372

Cc1cc(N2CCN(C(=O)Nc3ccccc3)CC2)ccc1NC(=O)c1nc[nH]c1C(=O)Nc1nc2ccccc2[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.47
TDP1 Q9NUW8 1/20 0.47
KMT2A Q03164 4/20 0.42
ALDH1A1 P00352 3/20 0.42
MAPT P10636 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
USP2 O75604 1/20 0.41
GAA P10253 2/20 0.41
DGAT1 O75907 1/20 0.40
JAK1 P23458 1/20 0.40
PTGDR Q13258 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MEN1 O00255 3/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
HSD17B10 Q99714 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
ME2 P23368 1/20 0.39
ME1 P48163 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL215188 0.92 KDM4E (0.46) KDM4ETDP1KMT2AALDH1A1MAPT
SCHEMBL2735376 0.91 GAA (0.42) KDM4ETDP1KMT2AALDH1A1MAPT
SCHEMBL2735381 0.88 ABCB1 (0.47) KDM4ETDP1KMT2AALDH1A1MAPT
SCHEMBL2735358 0.88 GAA (0.44) KDM4ETDP1KMT2AALDH1A1MAPT
SCHEMBL2735382 0.87 NPC1 (0.46) KDM4ETDP1KMT2AALDH1A1MAPT
SCHEMBL215034 0.87 ATM (0.44) KDM4ETDP1KMT2AMAPTSMN1; SMN2
SCHEMBL2735371 0.86 PTGDR (0.53) KDM4ETDP1KMT2AALDH1A1MAPT
SCHEMBL2759942 0.80 NPC1 (0.54) KDM4ETDP1KMT2AALDH1A1MAPT
SCHEMBL2735336 0.79 KCNH2 (0.42) KDM4ETDP1KMT2AALDH1A1MAPT
SCHEMBL214896 0.79 NPC1 (0.52) KDM4ETDP1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 KDM4E 952/4885TDP1 3233/4885KMT2A 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.